The MIC90 of glycylcycline (< or =0.06 mg/L) against 55 strains of Streptococcus pneumoniae was 100-fold lower than that of minocycline or tetracycline. In a mouse model of penicillin-resistant S. pneumoniae (PRSP) pneumonia, glycylcycline (10 mg/kg) decreased bacterial counts in the lungs from 10(6) cfu to <10(2) cfu, whereas no apparent reduction of bacterial numbers was observed with minocycline or penicillin G. Pharmacokinetic studies showed that the half-life and area under the curve of glycylcycline were superior to those of minocycline and penicillin G in the lungs. These results show a preferential distribution of glycylcycline in the lungs and potent in vivo bactericidal activity in PRSP pneumonia.

1998-10-01·Antimicrobial agents and chemotherapy2区 · 医学

In Vitro Activities of 15 Antimicrobial Agents against Clinical Isolates of South African Enterococci

2区 · 医学

Article

作者: Struwig, M. C. ; Botha, P. L. ; Chalkley, L. J.

ABSTRACT:

The activities of a panel of currently available antibiotics and the investigational agents LY 333328, linezolid, CL 331,002, CL 329,998, moxifloxacin (BAY 12-8039), trovafloxacin, and quinupristin-dalfopristin against 274 clinical isolates of enterococci were determined. No vancomycin resistance or β-lactamase production was observed. Except for 12 isolates (all non- Enterococcus faecalis ) showing reduced susceptibility to quinupristin-dalfopristin (MIC, ≥4 μg/ml), the new agents exhibited promising in vitro antienterococcal activity.

1997-11-01·Antimicrobial agents and chemotherapy2区 · 医学

In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium

2区 · 医学

Article

作者: Mercier, R C ; Rybak, M J ; Penzak, S R

We evaluated the in vitro activities of clinafloxacin, CL331,002, LY333328, quinupristin dalfopristin, and eperezolid (formerly known as U-100,592) against four strains of enterococci. All regimens tested resulted in the growth inhibition of each isolate. Against the three clinafloxacin-susceptible strains, clinafloxacin tested alone was the most active treatment, decreasing the bacterial inoculum by more than 3 log10 CFU/ml after 24 h in time-kill curve studies.

100 项与 CL-331002 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肠球菌感染	临床前	美国	Beth Israel Medical Center	1997-03-02
革兰氏阳性细菌感染	临床前	美国	Beth Israel Medical Center	1997-03-02
耐甲氧西林金黄色葡萄球菌感染	临床前	美国	New England Deaconess Hospital	1994-03-01
细菌感染	药物发现	美国	Lederle Laboratories	-